Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Bausch + Lomb Corporation
BLCO
NYSE·Healthcare·Medical - Instruments & Supplies·Mkt cap $5.9B
$17.22
▲ +4.02%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$13.09 - $18.92
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 20.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- 170+ year heritage and brand recognition in eye health
- Diversified product portfolio across three complementary segments
- Extensive global distribution network and market penetration
- Proprietary pharmaceutical formulations and surgical technology
Bear Case
2 risks
- Low volatility (beta 0.6).
- Premium valuation to Medical Devices peers
Growth
Turning profitable
Aging global population increasing demand for eye care treatments
Value
Premium valuation to Medical Devices peers
Momentum
Stable
+0.4% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying BLCO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 29, 2026
APR 29, 2026
Reported EPS of $0.08 vs $0.06 consensus (+33.3% surprise). Revenue of $1.2B vs $1.2B expected (+2.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+33.3%
Next: Jul 29, 2026
Revenue trend · last 8Q
—
—
—
—
+5%
+7%
+10%
+9%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.2B
$1.2B
$1.3B
$1.1B
$1.3B
$1.3B
$1.4B
$1.2B
Margins · last 8Q
Gross
56.6%
Operating
4.7%
Profit
-5.7%
Wall Street consensus
6 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
$16.00
▼ -7.1% vs $17.22
Latest: Evercore · Apr 30, 2026
1 analyst covering